Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Galectin Therapeutics Inc

PHPN
Current price
2.6 EUR -0.12 EUR (-4.41%)
Last closed 2.9 USD
ISIN US3632252025
Sector Healthcare
Industry Biotechnology
Exchange Frankfurt Exchange
Capitalization 179 983 712 USD
Yield for 12 month +47.06 %
1Y
3Y
5Y
10Y
15Y
PHPN
21.11.2021 - 28.11.2021

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia. Address: 4960 Peachtree Industrial Boulevard, Norcross, GA, United States, 30071

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

11 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

-33 000 USD

Last Year

-32 000 USD

Current Quarter

-9 000 USD

Last Quarter

-9 000 USD

Key Figures PHPN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA
Operating Margin TTM
PE Ratio
Return On Assets TTM -103.87 %
PEG Ratio
Return On Equity TTM -3727.95 %
Wall Street Target Price 11 USD
Revenue TTM
Book Value -1.36 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings per share -0.78 USD
Diluted Eps TTM -0.78 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics PHPN

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History PHPN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:6
Payout Ratio
Last Split Date 23.03.2012
Dividend Date

Stock Valuation PHPN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA -4.0392
Price Book MRQ 207.6975

Financials PHPN

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators PHPN

For 52 weeks

1.56 USD 4.27 USD
50 Day MA 2.65 USD
Shares Short Prior Month 5 376 378
200 Day MA 2.55 USD
Short Ratio 42.54
Shares Short 5 459 503
Short Percent 18.22 %